Table 1 Baseline clinical characteristics of patients enrolled in this study.

From: Composition and Interactions of Hepatitis B Virus Quasispecies Defined the Virological Response During Telbivudine Therapy

Groups

CVR (N = 10)

VB (N = 10)

PVR (N = 10)

P-value

Male

8

7

9

0.535

Age, years

31.2 ± 11.2

37.3 ± 11.3

29.3 ± 7.8

0.206

HBV sub-genotype

   

0.287

B2

6

3

3

 

C2

4

7

7

 

Baseline HBV DNA levels, Log10 copies/mL

Median (range)

8.95 (7.68–9.72)

9.19 (8.31–10.42)

9.26 (7.99–9.78)

0.371

Mean ± SD

8.86 ± 0.62

9.23 ± 0.75

9.11 ± 0.58

0.431

Baseline HBsAg levels, Log10 IU/mL

Median (range)

4.45 (3.18–4.98)

4.70 (3.71–5.46)

4.54 (3.35–4.74)

0.939

Mean ± SD

4.34 ± 0.56

4.66 ± 0.63

4.35 ± 0.44

0.347

Baseline ALT Levels, IU/mL

Median (range)

150.65 (91–676)

116.45 (45–193)

126.95 (82–622)

0.196

  1. Notes: HBV DNA levels were determined using Roche COBAS TaqMan. HBsAg levels were assayed using ARCHITECT i2000SR. CVR: complete virological response group; PVR: partial virological response group; VB: virological breakthrough group; ALT: alanine aminotransferase; ULN, upper limit of normal; and HBsAg, hepatitis B surface antigen.
Back to article page